Bumble Inc vs Gilead Sciences, Inc. — how do they compare? Bumble Inc trades at $2.66 (market cap $366.87M), while Gilead Sciences, Inc. trades at $136.68 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 458.9× Bumble Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Bumble Inc pays none. Which is the better fit depends on your goals.
| BMBL | GILD | |
|---|---|---|
Market Cap | $366.87M | $168.35B |
Sector | Technology | Health |
52-Week High | $7.17 | $155.80 |
52-Week Low | $2.70 | $110.56 |
Enterprise Value | $672.73M | $191.42B |
Dividend Yield | — | 2.42% |
Signals from Pluang's Aura AI — not financial advice
BMBL trades at $2.73, down 3.53% on the day, with a bearish technical outlook. The company reported a Q2 2026 earnings miss and negative net income margin of -57.96%, though revenue of $965.66M in 2025 shows scale. Recent news highlights a major shift in its women-first messaging policy to boost engagement amid slowing growth and exploration of a potential sale.
The outlook is challenged by persistent losses and declining paying users, but a low P/S of 0.38 offers valuation appeal. Risks include execution of product changes and intense competition. Analysts are mostly neutral with a $3.62 price target, suggesting cautious optimism if turnaround efforts succeed.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Trailing returns across standard periods
Latest headlines on both assets
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →